Stability of dobutamine in continuous ambulatory delivery devices

Madfai, Farah Al; Valah, B.; Zaidi, Syed Tabish Razi; Wanandy, Troy; Ming, Long Chiau; Peterson, Gregory M.; Patel, Rahul P.

doi:10.1111/jcpt.12674

Cited by 2 publications

(1 citation statement)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our study also shows that pH decreased with increasing drug concentration, which is consistent with findings from a previous study . Furthermore, it was reported that the delta pH was <0.2 (our study: delta pH ≤ 0.12), indicating essentially unchanged pH . The admixture appearance and pH measurement indicated that etoposide, epirubicin hydrochloride and vindesine sulphate were physically compatible in the admixtures …”

Section: Discussionsupporting

confidence: 92%

In vitro compatibility and stability of admixtures containing etoposide, epirubicin hydrochloride and vindesine sulphate in a single infusion bag

Yan

et al. 2019

J Clin Pharm Ther

View full text Add to dashboard Cite

What is known and objectives: The etoposide, doxorubicin hydrochloride, vincristine sulphate, cyclophosphamide and prednisone (EPOCH) chemotherapy regimen is effective in patients with relapsed or refractory non-Hodgkin's lymphoma. However, vincristine and doxorubicin hydrochloride are relatively toxic, leading to neurovirulence and cardiotoxicity, respectively. In this study, we replaced these drugs with vindesine and epirubicin hydrochloride to reduce the cardiotoxicity and evaluated admixtures containing these drugs along with etoposide in a single infusion bag in vitro. Methods:The appearance and pH of the admixtures were evaluated, and the number of particles was detected. High-performance liquid chromatography was used to measure the concentration and degradation rates of etoposide, epirubicin hydrochloride and vindesine sulphate in each admixture. Results and discussion: No precipitation occurred when mixing clinically relevant concentrations of etoposide, epirubicin hydrochloride and vindesine sulphate in a 0.9% NaCl injection solution. Furthermore, the delta pH of the admixtures was ≤0.12 throughout the experiment, and the number of particles (≥10 and ≥25 μm) in the solutions over the 24 hours post-preparation period met USP standards. Etoposide, epirubicin hydrochloride and vindesine sulphate were retained at >96% of their initial concentrations in the admixtures at 25°C over the course of the experiment. Etoposide, epirubicin hydrochloride and vindesine sulphate are compatible when mixed in a 0.9% NaCl injection solution, and the admixtures are stable for at least 24 hours when stored in infusion bags. What is new and conclusion: This in vitro analysis indicates the suitability of our novel admixtures containing less toxic drug equivalents in a single infusion bag for clinical application. K E Y W O R D S admixture, compatibility, epirubicin hydrochloride, etoposide, stability, vindesine sulphate

show abstract

Section: Discussionsupporting

confidence: 92%